Clinical Scorecard: The Impact of Academia-Industry Separation on the Timeliness of New Treatment Availability
At a Glance
Category
Detail
Condition
Drug-resistant epilepsy and other conditions requiring new antiseizure medications
Key Mechanisms
Separation of academia from pharmaceutical industry reduces clinical trial participation and delays adoption of new treatments
Target Population
Patients with drug-resistant epilepsy and other neurological conditions requiring new therapies
Care Setting
Academic medical centers, clinical practice, and pharmaceutical research settings
Key Highlights
Ethical concerns led to academia distancing from pharmaceutical industry, reducing collaboration in clinical trials.
Industry develops and obtains regulatory approval for new drugs, relying on academic centers for trial enrollment.
Reduced academic involvement has slowed adoption of effective new antiseizure medications, delaying patient access.
Guideline-Based Recommendations
Diagnosis
Recognize drug-resistant epilepsy as a condition affecting approximately one-third of epilepsy patients.
Identify candidates for new antiseizure medications based on clinical trial evidence.
Management
Encourage collaboration between academia and industry for clinical trial participation to facilitate timely access to new treatments.
Promote early adoption of newly approved antiseizure medications in academic centers to lead wider clinical use.
Monitoring & Follow-up
Track uptake rates of new antiseizure medications in academic and clinical settings.
Monitor patient outcomes to assess effectiveness of recently approved therapies.
Risks
Delayed adoption of effective treatments may prolong patient suffering and reduce therapeutic benefits.
Excessive separation between academia and industry may hinder clinical research progress and knowledge dissemination.
Patient & Prescribing Data
Patients with drug-resistant epilepsy and Dravet syndrome in the USA, Canada, and Europe
New antiseizure medications like cenobamate and fenfluramine show superior efficacy but have slow adoption rates, with only about 10% of eligible patients treated within four years of approval.
Clinical Best Practices
Maintain transparent and ethical collaborations between academic institutions and pharmaceutical industry focused on research and development.
Support academic participation in clinical trials to enhance familiarity and early adoption of new therapies.
Educate clinicians in academic centers about emerging treatments to lead broader clinical uptake.
Balance ethical concerns with the need for timely patient access to innovative treatments.
